Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.

Oncology reports - 1 May 2013

Li Xiao-You, Wu Jian-Zhong, Cao Hai-Xia, Ma Rong, Wu Jian-Qiu, Zhong Yue-Jiao, Feng Ji-Feng

Abstract excerpt

The sensitivity of lung cancer to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) has been found to be associated with mutations in the tyrosine kinase domain of EGFR. However, not all mutations are sensitive to gefitinib. While CpG island methylation in the promoter region of the EGFR gene and transcriptional silencing are common in solid tumors, the role of the EGFR gene promoter...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azacitidine
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Survival

Share to CpG Islands

Share to Decitabine

Share to Gefitinib

Share to Protein Kinase Inhibitors

Share to Quinazolines

Source

Identifiers

PMID: 23440266
DOI: 10.3892/or.2013.2298

Genes

EGFR
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.PMID 23440266Read ↗

Monitoring EGFR-lung cancer evolution: a possible beginning of a “methylation era” in TKI resistance predictionSemantic proximity Read ↗

Methylation-modulated PFTK1 regulates gefitinib resistance via Wnt/β-catenin signaling in EGFR mutant non-small-cell lung cancer cells.Semantic proximity Read ↗

5' cytosine-phospho-guanine island methylation is responsible for p14ARF inactivation and inversely correlates with p53 overexpression in resected non-small cell lung cancer.Semantic proximity Read ↗

Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.Semantic proximity Read ↗

Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.Semantic proximity Read ↗

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer.Semantic proximity Read ↗

Inhibition of DNA‑PK by gefitinib causes synergism between gefitinib and cisplatin in NSCLC.Semantic proximity Read ↗

Suppression of DNA methyltransferase 1 levels in head and neck squamous carcinoma cells using small interfering RNA results in growth inhibition and increase in Cdk inhibitor p21.Semantic proximity Read ↗

MDM2 Overexpression Deregulates the Transcriptional Control of RB/E2F Leading to DNA Methyltransferase 3A Overexpression in Lung CancerSemantic proximity Read ↗

Epigenetic Therapy of Non-Small Cell Lung Cancer Using Decitabine (5-Aza-2′-Deoxycytidine)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.